News and Trends 17 Oct 2022 Ophthalmology biopharma company Oculis combines with EBAC …Other candidates In addition to these three clinical candidates, Oculis is engaged in several earlier preclinical development initiatives, including the evaluation of OCS-03 as a possible treatment for corneal neovascularization,… October 17, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022 Poolbeg identifies new potential drug candidates for RSV infections Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in… December 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Poolbeg to investigate melioidosis vaccine candidate Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease… September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 May 2023 Scientists create first CRISPR-based drug candidate targeting the microbiome A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve… May 10, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2024 Biotechs in the US Capital: seven key players based in Washington DC …to specific genetic variants in the IGHMBP2 gene. The second candidate, VTR-297, is a novel topical antifungal candidate aimed at treating onychomycosis. This condition, affecting up to 14% of the… February 20, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Companies come together in fight against Dengue Fever …vaccine candidate. The agreement initially focuses on Emergex’s dengue vaccine candidate and also includes the shared development and commercialization of COVID-19 and Chikungunya vaccine candidates. Emergex’s Dengue and COVID-19 vaccine… July 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Jan 2024 Eight mental health biotech companies trying to make a difference to people’s lives …get better faster. The company’s clinical pipeline includes novel drug candidates for depression, post-traumatic stress disorder (PTSD), schizophrenia, and other mental health conditions. It also has its own biomarker platform… January 25, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2025 Depression drug trials are failing—and placebos are to blame …effect is,” the study read. Depression candidate Supernus’ SPN-820 fails in phase 2b clinical trial; Actinogen blames placebos This was seen with American biotech Supernus Pharmaceuticals’ depression candidate SPN-820, which… March 21, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2024 Why is the immunology and inflammation market suddenly attracting a wave of investment? …biomedical advancements in the basic science of immunology combined with productizing therapeutic antibodies enabled the second wave. Here, doctors could finally direct an antibody at a defined immune target, allowing… July 30, 2024 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic …to attack tumors by binding the CD40 co-stimulatory molecule on dendritic cells. The antibody may also kill cancer cells directly through a second mechanism. The candidate has already been tested… January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2017 PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody …round of investment in ChemomAb, an Israeli startup developing a monoclonal antibody to treat nonalcoholic steatohepatitis (NASH). ChemomAb’s antibody, CM-101, is fully humanized and targets a newly discovered protein that… December 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment… December 14, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email